Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Daily Top 10 COVID-19 papers DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM

Ischemic Heart Disease

Free Subscription Articles published in Blood Retrieve available abstracts of 7 articles: HTML format

Single Articles

November 2019
1. AHN IE
   Cardiovascular adverse events of ibrutinib.
   Blood. 2019;134:1881-1882.
   PubMed    
   
   
   October 2019
2. DICKERSON T, Wiczer T, Waller A, Philippon J, et al
   Hypertension and Incident Cardiovascular Events Following Ibrutinib Initiation.
   Blood. 2019 Oct 3. pii: blood.2019000840. doi: 10.1182/blood.2019000840.
   PubMed     Abstract available
   
   
   February 2019
3. DE VRIES PS, Sabater-Lleal M, Huffman JE, Marten J, et al
   A genome-wide association study identifies new loci for factor VII and implicates factor VII in ischemic stroke etiology.
   Blood. 2019;133:967-977.
   PubMed     Abstract available
   
   
   
4. NAVI BB, Reiner AS, Kamel H, Iadecola C, et al
   Arterial thromboembolic events preceding the diagnosis of cancer in older persons.
   Blood. 2019;133:781-789.
   PubMed     Abstract available
   
   
   January 2019
5. LATIFI Y, Moccetti F, Wu M, Xie A, et al
   Thrombotic microangipathy as a cause for cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.
   Blood. 2019 Jan 28. pii: blood-2018-10-881557. doi: 10.1182/blood-2018-10-881557
   PubMed     Abstract available
   
   
   October 2018
6. SCHNEPPENHEIM R, Hellermann N, Brehm MA, Klemm U, et al
   The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction.
   Blood. 2018 Oct 26. pii: blood-2018-04-843425. doi: 10.1182/blood-2018-04-843425
   PubMed     Abstract available
   
   
   December 2017
7. NAZIR S, Gadi I, Al-Dabet MM, Elwakiel A, et al
   Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition.
   Blood. 2017;130:2664-2677.
   PubMed     Abstract available
   
   

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: